147290-67-3

Usage

InChI:InChI=1/C12H15NO4/c1-8-7-9(5-6-10(8)13(15)16)11(14)17-12(2,3)4/h5-7H,1-4H3

Upstream product

• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 934481-43-3 4-amino-3-methyl-benzoic acid tert-butyl ester 
• 171049-45-9 [7-(4-{Amino-[(Z)-benzyloxycarbonylimino]-methyl}-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 147290-71-9 2-{4-tert-Butoxycarbonyl-2-[(tert-butoxycarbonyl-phenethyl-amino)-methyl]-phenylamino}-succinic acid dimethyl ester 
• 292135-38-7 [7-(4-Carbamimidoyl-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 171049-34-6 methyl 7-carboxy-3-oxo-1,4-benzodiazepine-2-acetate 
• 147290-69-5 t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate 
• 147290-70-8 tert-butyl 4-amino-3-[[N-(tert-butoxycarbonyl)-N-phenethylamino]methyl]benzoate 
• 147290-68-4 t-butyl 4-nitro-3-[N-(2-phenylethyl)aminomethyl]benzoate 
• 446263-90-7 tert-butyl-4-nitro-3-[(N-methylacetylamino)methyl]benzoate 
• 334999-61-0 tert-butyl 3-[(N-acetyl-N-methylamino)methyl]-4-aminobenzoate 
• 171049-68-6 tert-butyl 3-(3-methylaminomethyl)-4-nitrobenzoate 
• 171049-67-5 tert-butyl-3-(bromomethyl)-4-nitrobenzoate 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5 and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds. [image]

Fab I inhibitors

Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment of bacterial infections.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began w

Bicyclic fibrinogen antagonists

PCT No. PCT/US95/00248 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Jan. 9, 1995 PCT Pub. No. WO96/18619 PCT Pub. Date Jul. 13, 1995Certain compounds within formula (I) are inhibitors of platelet aggregation: wherein A1 is NH or CH2;

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formula: STR1 wherein A1 to A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N wherein S and N may be optionally oxidized; D1 to D4 form an accessible substituted six membered ring, optionally containing up to two nitrogen atoms; R is at least one substituent chosen from the group of R7, or Q--C1-4 alkyl, Q--C2-4 alkenyl, Q--C2-4 alkynyl, preferably substituted by an acidic function; R* is H, Q--C1-6 alkyl, Q--C1-6 oxoalkyl, Q--C2-6 alkenyl or Q--C2-4 alkynyl, C3-6 cycloalkyl, Ar or Het, optionally substituted by one or more substitutents; and R6 is preferably a substituent containing a basic nitrogen moiety; or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.